Correction to Amgen/Kyprolis Article
July 24 2015 - 3:21PM
Dow Jones News
"FDA Approves Amgen's Kyprolis as a Second-Line Multiple Myeloma
Treatment" at 12:55 p.m. ET incorrectly suggested that drug was
approved under an accelerated process.
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2024 to May 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From May 2023 to May 2024